Unconjugated DHEA Test · Blood

Your body's production of active sex hormones does not rely solely on the ovaries or testes. A large share of the testosterone and estrogen circulating in your tissues actually starts as a single molecule made by your adrenal glands: DHEA (dehydroepiandrosterone). This unconjugated, free form of DHEA is the version your cells can immediately grab and convert into the hormones that maintain bone density, muscle mass, skin health, and cognitive sharpness. Its levels peak in your twenties and then fall steeply, dropping by roughly 74% in men and 70% in women by the time you reach your fifties.

Most routine hormone panels skip this measurement entirely, and when doctors do check the DHEA system, they usually order the sulfated storage form, DHEA-S (dehydroepiandrosterone sulfate), which is more stable in blood. Unconjugated DHEA tells a slightly different story: it reflects the active, rapidly turning over fraction that is available for immediate conversion in your tissues. If you want to know how much raw material your adrenal glands are currently supplying for sex hormone production, this is the more direct measurement.

What Unconjugated DHEA Is and Where It Comes From

DHEA is a small steroid molecule, not a protein or enzyme. It belongs to a class of hormones called C19 steroids, named for their 19-carbon chemical skeleton. Your adrenal glands (specifically a layer called the zona reticularis) are the primary factory, though the ovaries, testes, and even the brain produce smaller amounts. Once released into the bloodstream, most DHEA is quickly converted to its sulfated storage form (DHEA-S) by a specific enzyme. What remains unconjugated is the fraction immediately available for conversion into more potent hormones.

Inside your tissues, unconjugated DHEA follows a conversion chain: it can become androstenedione, then testosterone, then either dihydrotestosterone (a potent androgen) or estradiol (the primary estrogen). This local, tissue-level hormone production, sometimes called intracrine metabolism, is especially significant for women after menopause, when adrenal DHEA becomes the dominant source of both androgens and estrogens.

The Age-Related Decline

DHEA and DHEA-S are among the most dramatically age-sensitive hormones in the human body. In a large cross-sectional study, serum DHEA declined by 74% in men and 70% in women between the 20 to 30 year old and 50 to 60 year old age groups, with smaller additional decreases after age 60. The downstream androgen metabolites tracked by conjugated markers fell by 41% to 73% over the full age range from 20 to 80 years.

This decline matters because women produce approximately 66% of the total androgen output found in men, and most of their androgens originate from the conversion of DHEA and DHEA-S in peripheral tissues. In men at age 50 to 60, the testes and DHEA each contribute approximately half of total androgen production. As the adrenal supply drops, the downstream hormone pool shrinks with it, potentially affecting bone, muscle, skin, and brain.

Heart Disease and Mortality

The strongest outcome data linking the DHEA system to hard clinical endpoints comes from studies measuring DHEA-S (the sulfated storage form, a related but different measurement from this test). A meta-analysis of 18 cohort studies in people with established cardiovascular disease found that those with the lowest DHEA-S levels had about 47% higher risk of death from any cause, about 58% higher risk of fatal cardiovascular events, and about 42% higher risk of nonfatal cardiovascular events compared to those with the highest levels.

A separate pooled analysis of 53 cohort studies covering over 359,000 people in the general population found that men in the highest third of DHEA-S had about 28% lower risk of dying from any cause compared to those in the lowest third. In women, the relationship was weaker and did not reach statistical significance. One study of disabled older women found a U-shaped pattern: both the lowest and highest DHEA-S groups had roughly double the mortality risk compared to the middle range.

Because these findings are based on DHEA-S rather than unconjugated DHEA, they provide strong directional evidence but cannot be assumed to apply identically to this specific test. The two forms are biologically connected, as unconjugated DHEA is the precursor that feeds the DHEA-S pool, but their blood levels can diverge depending on sulfation enzyme activity and clearance rates.

Bone Health in Women

A Mendelian randomization study, which uses genetic variants as natural experiments to test cause and effect, found that genetically predicted higher DHEA-S levels were causally linked to higher bone mineral density at the lumbar spine and lower risk of forearm fractures in women. This genetic evidence strengthens the case that the DHEA system genuinely protects bone in women, rather than just tracking overall health.

Randomized trials of oral DHEA supplementation (50 mg per day) in older adults have shown modest increases in bone mineral density at certain sites. In women specifically, lumbar spine density increased by about 1.7% after one year and 3.6% after two years of supplementation in one trial. Men saw smaller, less consistent bone effects. These trials measured DHEA-S as the monitoring marker, so the direct link to unconjugated DHEA levels has not been separately confirmed.

Cognitive Function

In a study of 295 community-dwelling women, higher DHEA-S levels were independently associated with better executive function, concentration, and working memory after adjusting for age, education, mood, and other hormones. This association was observed with DHEA-S specifically. Whether unconjugated DHEA tracks the same cognitive patterns has not been directly tested in a comparable study, though the two forms are metabolically linked.

What High Levels May Signal

While age-related decline gets the most attention, elevated unconjugated DHEA or DHEA-S can also be clinically meaningful. In reproductive-age women, high levels often point toward excess androgen production from the adrenals or ovaries. This pattern is commonly seen in polycystic ovary syndrome (PCOS), where DHEA-S is used as a second-line marker of androgen excess after total and free testosterone.

Very high values that are clearly above the age and sex reference range can also flag more serious conditions, including adrenal tumors or congenital adrenal hyperplasia (an inherited enzyme deficiency that redirects steroid production toward androgens). A markedly elevated result warrants further investigation with imaging and additional hormone testing.

Understanding Your Results: Unconjugated DHEA vs. DHEA-S

This distinction matters more than most people realize. DHEA-S is the far more abundant form in blood (it circulates at roughly 300 to 500 times the concentration of unconjugated DHEA), has a much longer half-life, and shows less hour-to-hour fluctuation. Because of this stability, DHEA-S is the standard clinical marker for most diagnostic purposes, including screening for adrenal insufficiency, adrenal tumors, and PCOS.

Unconjugated DHEA, by contrast, has a pronounced circadian rhythm, with higher values in the morning that decline within a few hours of waking. It reflects the immediate, active fraction of adrenal androgen output. This makes it more sensitive to acute changes but also more variable from one blood draw to the next. A single reading can be misleading if timing is not controlled.

Reference Ranges

Standardized clinical reference ranges for unconjugated DHEA are less well established than those for DHEA-S. Most published ranges come from individual labs or research cohorts rather than from international consensus guidelines. The ranges below are drawn from population-based research using liquid chromatography-mass spectrometry (a highly accurate measurement method), but your lab may report different numbers depending on the assay used. These should be treated as orientation, not absolute targets.

In reproductive-age women (18 to 39 years), one large Australian study using LC-MS/MS reported a median unconjugated DHEA of approximately 4.91 nmol/L (roughly 142 ng/dL), with a range spanning from about 2 ng/dL to 678 ng/dL. All measured C19 androgens, including DHEA, were significantly lower in women aged 35 to 39 compared to those aged 18 to 25, confirming that the decline begins well before menopause. Age- and sex-stratified reference ranges for unconjugated DHEA in ng/dL are not yet standardized across labs. Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

Unconjugated DHEA is more variable than DHEA-S, making single readings easier to misinterpret. The most common confounders include:

• Time of day: Unconjugated DHEA follows a circadian pattern, with morning levels significantly higher than afternoon levels. Drawing blood at different times of day can produce meaningfully different results. Always draw in the early morning, ideally at the same time for serial comparisons.
• Acute stress: DHEA rises acutely in response to mental or physical stress, peaking at the end of the stressor and returning to baseline within about an hour. A blood draw taken during or immediately after a stressful event will be artificially elevated.
• Exogenous DHEA supplements: Over-the-counter DHEA capsules profoundly raise unconjugated DHEA levels. If you are taking DHEA and want to assess your body's own production, you need to stop supplementation for an appropriate washout period before testing.
• Corticosteroid use: Chronic or high-dose corticosteroids (prednisone, dexamethasone) suppress the entire adrenal hormone axis, lowering DHEA production. This reflects real adrenal suppression from the medication, not a primary adrenal problem.

Tracking Your Trend

Because unconjugated DHEA has meaningful day-to-day and circadian variability, a single reading provides limited information. The real value of this test comes from tracking your trajectory over time. A single low result could reflect testing at the wrong time of day, recent stress, or normal variation. Two or three concordant results, drawn at the same time of morning and under similar conditions, give you a much clearer picture of your actual adrenal androgen output.

If you are using this test to monitor DHEA supplementation, get a baseline before starting, then retest 4 to 6 weeks into supplementation to see whether your levels have reached the intended range. After that, check every 6 to 12 months. If you are tracking the natural age-related decline for prevention purposes, an annual morning draw gives you a useful trend line. The goal is to see your personal trajectory, not to hit a single magic number.

What to Do With an Abnormal Result

If your unconjugated DHEA comes back low for your age and sex, the first step is to confirm it with a repeat test drawn under proper conditions (early morning, fasting, no recent acute stress, no exogenous DHEA). A confirmed low result is most useful when interpreted alongside DHEA-S, cortisol, total and free testosterone, and estradiol. Together, these markers paint a picture of whether the issue is isolated to adrenal androgen production or part of a broader hormonal pattern.

If levels are unexpectedly high, especially in a woman with symptoms like acne, excess hair growth, or irregular periods, the workup should include total and free testosterone, androstenedione, and DHEA-S to distinguish between ovarian and adrenal sources of androgen excess. Very high values in either sex warrant imaging of the adrenal glands and referral to an endocrinologist.

For someone with confirmed age-related decline and no specific disease, the decision about whether to supplement is nuanced. Randomized trials of oral DHEA show reliable restoration of young-adult hormone levels, but clinical benefits on body composition, strength, cognition, and quality of life have been modest and inconsistent. The clearest benefits have been seen in bone density for older women and in quality of life for women with adrenal insufficiency. Discuss the risk-benefit tradeoff, including potential androgenic side effects in women (acne, voice changes, unwanted hair growth) and theoretical concerns about hormone-sensitive cancers, with a physician who understands hormone optimization.